Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in South Korea / NCT06330870
Recruiting Not applicable

Brain Metastasis Development Mechanism in BCBM Patients

NCT06330870 · tracked via the Priya Life Science South Korea tracker
Sponsor
Samsung Medical Center
Phase
Not applicable
Started
2023-04-06
Last updated
2024-03-26

Condition(s) studied

Breast CancerBrain Metastasis

Investigational drug(s) / intervention(s)

WGS/TME evaluation

WGS/TME evaluation: WGS/TME evaluation with blood and brain metastasis tissue during brain metastasis curative surgery

Study summary

This study is the experimental study for brain metastasis development mechanism in patients with breast cancer with brain metastasis

Eligibility

Sex
FEMALE
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Breast cancer * Brain metastasis curative surgery patient Exclusion Criteria: * Gamma Knife surgery patient

Primary outcome measure(s)

  • Intracranial disease free survival — Months
    Time to new brain metastasis or brain metastasis progression from the brain surgery

Trial sites (1)

FacilityCityRegionStatus
Ji-Yeon Kim Seoul South Korea Recruiting

More Samsung Medical Center trials in South Korea

Prospective Pecutaneous Coronary Intervention Registry Recruiting
Radiotherapy Dose Adaptation Based on Tumor Biology in Patients With cN2b-N3 Breast Cancer Recruiting
Clinical Application of Genetic Sequencing of Early Gastric Cancer and Gastric Adenoma Patients Recruiting
INsTantenous wavE-Free Ratio-guided PCI Versus Fractional Flow REserve-Guided PCI in rouTine Clinical Practice, Prospective, Multicenter Registry Active, not recruiting
Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism Starting soon

Other trials for the same condition

The OPBC-07/microNAC Study Active, not recruiting
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) Recruiting
Pharmacopuncture for Aromatase Inhibitor Induced Arthralgia (AIA) Recruiting
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer Active, not recruiting
Omission of Axillary Lymph Node Dissection in Case of Tumor Spread to Lymph Nodes in the Armpit in Breast Cancer Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06330870 on ClinicalTrials.gov ↗ ← All trials in South Korea